NOV 2-3 2016
Clinical Diagnostics & Research
34 101 17515

The 7th annual Clinical Diagnostics & Research conference is now On Demand!  This premiere venue discusses the latest advances in clinical diagnostics, research and medicine. The conference has proven to be a great success in disseminating knowledge and encouraging collaboration and connections between colleagues. View this conference at no charge, at any time!

Clinical Diagnostics & Research 2016 features informative presentations from keynote speakers and experts including; Dr. Scott Weiss, Dr. William Clarke, Dr. Ravinder Singh, Dr. Damian Grusom, and Dr. Lee Schroeder. Check out the virtual conference to view these and other great speakers at your convenience.

Watch this video to learn more about this year's exciting conference!

Our virtual conference allows you to participate in a global setting with no travel or cost to you. You can participate in exactly those parts which you are interested in and be back at your desk or bench in an instant. Virtual events remove time and place restrictions and ensure that everyone who wants to participate can do so.

Clinical Diagnostics & Research 2016 covers topics including:
 

FDA Regulation in Clinical Labs from a laboratory perspective, an FDA perspective, and other regulations and international standards

Precision Medicine Symposium with a basic research update, focus on clinical utility and application, reimbursement and logistical limitations in practical care, and pharmacogenetics

Point of Care Discussion, including hospital management challenges, working in a clinical environment or under-resourced areas and bringing opportunity to these areas, and FDA guidance in critical care

Lab Automation in clinical microbiology, pre-analytical automation, and routine chemistry

Pain Management associated with opiate addiction, laboratory interface with clinics, CDC guidelines, logistic challenges with testing, and reimbursement

Informatics and Big Data including electronic medical records and data repositories


Use #LRclinical to follow the conversation

Here are continuing medical education (CME) learner objectives that attendees should be able to do as a result of participating in this activity.
 

  • Ability to contrast previous and newly released guidelines
  • Take action to increase partnership and collaboration with clinicians
  • Identify actions that can be taken to deliver quality results faster to clinicians
  • Better define personalized healthcare today and explain the role of companion diagnostics
  • Better describe diagnostic tools used in the patient workups
  • Better describe how the evolution of laboratory testing in health has impacted the patient
  • Identify the role of the clinical laboratory in contributing to or preventing diagnostic errors
  • Identify laboratory directed interventions that can reduce diagnostic errors
  • Describe analytical issues associated with various assays
  • Recognize the patient safety risks associated with misuse of the clinical laboratory
  • Identify several categories of commonly misused laboratory tests
  • Advise patients on the likely long term effects of certain surgery in patients with diseases
  • Explain levels of personalized medicine as it attempts to predict individual response to therapy

Speakers:

Show Resources
Agenda
All times are Pacific Time
  • NOV 02, 2016 06:00 AM PDT
    Speaker: Anika Joeker, PhD
  • NOV 02, 2016 06:00 AM PDT
    Speaker: Jennifer Colby, PhD, DABCC, FACB
  • NOV 02, 2016 07:30 AM PDT
    Speaker: Ravinder Singh, PhD
  • NOV 02, 2016 09:00 AM PDT
    Augusto Litonjua, MD, PhD
    Associate Professor Channing Division of Network Medici...
    Scott Weiss, MD, MS
    Professor of Medicine, Harvard Medical School, Director...
  • NOV 02, 2016 10:30 AM PDT
    Speaker: Brian McNally, PhD
  • NOV 02, 2016 10:30 AM PDT
    Speaker: William Clarke, PhD, MBA, DABCC
  • NOV 02, 2016 10:30 AM PDT
    Speaker: Sebastiano Gattoni-Celli, MD
  • NOV 02, 2016 12:00 PM PDT
    Speaker: Nihmat Morjana, Ph.D., M.Sc.
  • NOV 02, 2016 01:30 PM PDT
    Speaker: John McDevitt, PhD
  • NOV 03, 2016 06:00 AM PDT
    Speaker: Damien Gruson, PhD
  • NOV 03, 2016 06:00 AM PDT
    Speaker: Steven Cotten, PhD DABCC
  • NOV 03, 2016 06:00 AM PDT
    Gerd Michel, PhD
    VP of R&D and Chief Scientific Officer Vela Research
    Lou Welebob
    Director, Vela Research Singapore
  • NOV 03, 2016 07:30 AM PDT
    Speaker: Raed Samara, PhD
  • NOV 03, 2016 09:00 AM PDT
    Speaker: Lee Schroeder, MD, PhD
  • NOV 03, 2016 10:30 AM PDT
    Speaker: James Snider, PhD
  • NOV 03, 2016 10:30 AM PDT
    Speaker: Keith Pardee, PhD
  • NOV 03, 2016 10:30 AM PDT
    Speaker: Natalie Rasmussen
  • NOV 03, 2016 12:00 PM PDT
    Speaker: Ellis Jacobs, PhD, DABCC, FACB
  • NOV 03, 2016 12:00 PM PDT
    Julie Deschenes, MBA, PhD
    Manager, Advanced Genomics Integrated Solutions
    Dilhan Weeraratne, PhD
    Senior Scientist, Advanced Genomics Support; QIAGEN Bio...
  • NOV 03, 2016 01:30 PM PDT
    Speaker: Fabrizio Bonelli, PhD
  • Clinical Research
  • NOV 02, 2016 06:00 AM PDT
    Speaker: Anika Joeker, PhD
  • NOV 02, 2016 10:30 AM PDT
    Speaker: Sebastiano Gattoni-Celli, MD
  • NOV 02, 2016 01:30 PM PDT
    Speaker: John McDevitt, PhD
  • NOV 03, 2016 10:30 AM PDT
    Speaker: Natalie Rasmussen
  • NOV 03, 2016 01:30 PM PDT
    Speaker: Fabrizio Bonelli, PhD
  • Pain Management
  • NOV 02, 2016 06:00 AM PDT
    Speaker: Jennifer Colby, PhD, DABCC, FACB
  • NOV 02, 2016 10:30 AM PDT
    Speaker: William Clarke, PhD, MBA, DABCC
  • NOV 02, 2016 12:00 PM PDT
    Speaker: Nihmat Morjana, Ph.D., M.Sc.
  • FDA Regulation in Clinical Labs
  • NOV 02, 2016 07:30 AM PDT
    Speaker: Ravinder Singh, PhD
  • Keynote
  • NOV 02, 2016 09:00 AM PDT
    Augusto Litonjua, MD, PhD
    Associate Professor Channing Division of Network Medici...
    Scott Weiss, MD, MS
    Professor of Medicine, Harvard Medical School, Director...
  • NOV 03, 2016 09:00 AM PDT
    Speaker: Lee Schroeder, MD, PhD
  • Industry
  • NOV 02, 2016 10:30 AM PDT
    Speaker: Brian McNally, PhD
  • NOV 03, 2016 06:00 AM PDT
    Gerd Michel, PhD
    VP of R&D and Chief Scientific Officer Vela Research
    Lou Welebob
    Director, Vela Research Singapore
  • NOV 03, 2016 07:30 AM PDT
    Speaker: Raed Samara, PhD
  • NOV 03, 2016 12:00 PM PDT
    Julie Deschenes, MBA, PhD
    Manager, Advanced Genomics Integrated Solutions
    Dilhan Weeraratne, PhD
    Senior Scientist, Advanced Genomics Support; QIAGEN Bio...
  • Lab Automation
  • NOV 03, 2016 06:00 AM PDT
    Speaker: Damien Gruson, PhD
  • Point of Care
  • NOV 03, 2016 06:00 AM PDT
    Speaker: Steven Cotten, PhD DABCC
  • NOV 03, 2016 10:30 AM PDT
    Speaker: James Snider, PhD
  • NOV 03, 2016 12:00 PM PDT
    Speaker: Ellis Jacobs, PhD, DABCC, FACB
  • Infectious Disease
  • NOV 03, 2016 10:30 AM PDT
    Speaker: Keith Pardee, PhD
Speakers

  • Augusto Litonjua, MD, PhD
    Associate Professor Channing Division of Network Medicine and Division of Pulmonary and Critical Care Medicine Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
    Biography
      Dr. Augusto A. Litonjua is a physician at Brigham and Women's Hospital (BWH). He is also an associate professor of medicine at Harvard Medical School. He received his medical degree from the University of the Philippines Manila (Manila, Philippines). He then completed a fellowship in internal medicine and a chief medical residency at The Brooklyn Hospital Center (formerly Brooklyn Hospital and Brooklyn - Caledonian Hospital). He also completed two fellowships: the first in pulmonary and critical care at West Virginia University Hospitals, and the second in pulmonary disease at BWH. He is board certified in critical care medicine, internal medicine and pulmonary disease. Dr. Litonjua's clinical interests include chronic obstructive pulmonary disease and asthma. His research examines the ways in which environmental exposures and genetic factors impact the development of asthma and lung function decline. He is currently studying the impact of vitamin D on lung disease, and his publications were the first to demonstrate that higher maternal vitamin D intake during pregnancy protects against lung-related illnesses in children. Dr. Litonjua has authored over 200 peer-reviewed publications and is the recipient of funding from the National Institutes of Health.
    • Scott Weiss, MD, MS
      Professor of Medicine, Harvard Medical School, Director, Partners HealthCare Personalized Medicine, Associate Director, Channing Division of Network Medicine
      Biography
        Scott Weiss is the Scientific Director of Partners HealthCare Personalized Medicine where he supervises a faculty of 6 and a staff of over 100 who are dedicated to translating the results of human genome research into clinical medical practice. His laboratory has close working relationships with the Department of Environmental Health at the Harvard School of Public Health, where he is a Professor of Environmental Health (Respiratory Biology Program), the Biostatistics Department at HSPH, the Pulmonary and Critical Care Division, and the Immunology Division, Department of Medicine, in Brigham and Women's Hospital.
      • Lee Schroeder, MD, PhD
        Assistant Professor of Pathology Director, Point of Care Testing Associate Director, Chemical Pathology; University of Michigan Hospital
        Biography
          Dr. Lee Schroeder is currently Assistant Professor at the University of Michigan where he is Director of Point-of-Care Testing and Associate Director of Chemical Pathology. His academic focus is at the interface of clinical informatics and health services research, using decision analytic approaches to model and improve the impact of laboratory medicine. This has included research involving laboratory capacity and quality improvement of sub-Saharan African laboratories, modeling the impact of different testing algorithms on health outcomes, and data mining the electronic medical record to better understand the performance of point-of-care testing. Lee Schroeder completed his BA in physics at the University of Pennsylvania in 1995, his MD/PhD with an NIH Medical Scientist Training Program scholarship award at the University of California, San Diego in 2011, and his pathology residency at Stanford University in 2014. Lee currently serves as Co-Director of a Blue Cross Blue Shield funded pilot program to improve utilization of genetic testing for hereditary cancer syndromes and is member of the chemistry resource committee at the College of American Pathologists.
        • Julie Deschenes, MBA, PhD
          Manager, Advanced Genomics Integrated Solutions
          Biography
            After completing in a B.S. in Biochemistry, Dr Deschênes obtained a Master in Pharmacology from University of Montréal, Canada focusing on the development of competitive antagonist for the Natriuretic Peptide Receptor B. She completed her Ph.D. in Biochemistry and Molecular Biology in 2008 at the Institute for Research in Immunology and Cancer (IRIC) in Montréal where she studied Breast Cancer by looking at the transcriptional regulation of estrogen receptor to the DNA through long-range regulation by estrogen. Dr Deschênes has been an author on numerous peer-reviewed articles and spoken on a variety of high-level panels, symposiums, and conference sessions. Dr. Deschênes joined QIAGEN in 2007 through Ingenuity Systems, now part of QIAGEN Bioinformatics and has since worked closely with customers and partner identifying insights in their NGS and expression analysis data as well helping the implementation of their clinical decision support software. She is a strong customer advocate thriving on partnering with customer to meet and exceed their needs. She recently obtained her Executive MBA on Market Strategy for a Next-Generation Sequencing Clinical Reporting Software from the Würzburg Universität, Germany while supporting the market entry of QIAGEN Clinical Insight Interpret.
          • Anika Joeker, PhD
            Director, Global Product Management, Clinical Program; QIAGEN Bioinformatics
            Biography
              Anika Joecker is a director in the global product management department in the clinical program of QIAGEN bioinformatics. She has been working in the field of bioinformatics for the last 15 years and worked as a bioinformatics group leader at the German Cancer Research Center before she joined CLC bio, now QIAGEN in 2011.
            • Raed Samara, PhD
              Global Product Manager, NGS, QIAGEN
              Biography
                Raed Samara, PhD is a Global Product Manager for NGS technologies at QIAGEN, with a focus on pre-analytics and targeted enrichment. Prior to joining QIAGEN, he was a postdoctoral fellow at the National Cancer Institute conducting research in the field of cancer immunology with emphasis on identifying strategies to boost the efficacy of cancer vaccines. He received his Ph.D. degree from Georgetown University in tumor biology.
              • Dilhan Weeraratne, PhD
                Senior Scientist, Advanced Genomics Support; QIAGEN Bioinformatics
                Biography
                  Dilhan Weeraratne is a cancer genomics scientist invested in leveraging the explosion of genomics data to transform cancer treatment and patient outcome. Dilhan has over a decade of experience in cancer genomics and precision oncology both in academic and industry settings. Dilhan obtained his PhD in neuroscience/molecular biology from University of Vermont in 2007. Subsequently, he joined Harvard Medical School and Broad institute, MIT to do postdoctoral research in medulloblastoma genomics. His work was instrumental in defining the currently WHO accepted molecular subgroups of Medulloblastoma. Dilhan's work on genomic landscape of medulloblastoma was published in the journal "Nature". Following his postdoctoral work, Dilhan transitioned to biopharma and worked at leading diagnostics companies including Thermo Fisher and N-of-One working on clinical interpretation and annotation of biomarkers in solid and hematological tumors, clinical reporting and developing pharmacogenomics biomarker knowledgebases. Dilhan Joined QIAGEN in May of 2016.
                • Natalie Rasmussen
                  R&D Specialist, ARUP
                  Biography
                    Natalie Rasmussen grew up in the Salt Lake City, UT area and earned a BS in biology from the University of Utah in 2004. She began working in the toxicology area at ARUP Laboratories in 2005, where she prepared samples and analyzed them via immunoassay and mass spectrometry. Natalie accepted a position as research and development specialist in ARUP's Institute for Clinical and Experimental Pathology in 2012, where she primarily works on Time-of-Flight mass spec-based testing. She also has some experience with immunoassay and MADLI-TOF. In her free time, she enjoys exploring the playground that is Utah by hiking and camping. She also enjoys reading, cooking, playing softball, and attending sporting events, especially at the University of Utah.
                  • Fabrizio Bonelli, PhD
                    Chief Scientific Officer, VP, DIASORIN Inc.
                    Biography
                      Fabrizio Bonelli is Chief Scientific Officer of the DIASORIN group. He has been working in the R&D Department of DIASORIN for 29 years, previously at the Italian site and since 2010 at the US site in Minnesota. Prior to joining DIASORIN he was a postdoctoral fellow at the National Cancer Institute in Bethesda, MD, conducting research in the field of cellular carcinogenesis and tumor promotion.
                    • Gerd Michel, PhD
                      VP of R&D and Chief Scientific Officer Vela Research
                      Biography
                        Dr. Gerd Michel obtained his PhD from the University of Heidelberg, Germany, where he was head of the Receptor Research Laboratory at the Dept. of Internal Medicine. After two years in the private laboratory sector he joined Abbott Laboratories as a founding member of their European Research unit, which grew from 3 to over 600 employees by the time he left. He spent more than 18 years with Abbott Diagnostics rising to the post of Director of Medical and Scientific Development for Europe, Middle East & Africa. Among various management functions he was responsible for OEM product development and the assessment of new technologies. He had numerous product successes including HCV, HIV and cardiac Troponin I tests that became state-of-the-art diagnostics worldwide. For over 7 years he held the position of STO at the Foundation of New Innovative Diagnostics (FIND) in Geneva. During this time he focused on the discovery of novel biomarkers for use in point-of-care detection of infectious diseases such as TB and malaria, mainly funded by the Bill & Melinda Gates Foundation. He became Vice President of R&D and Chief Technology Officer at Vela Research in Singapore in 2013, focusing on molecular and personalized diagnostics. He has received several industry and academic awards for his work, has (co-) authored >180 peer-reviewed publications and is an internationally requested speaker. He is also an inventor on a number of patents. He holds fellowships from the University of Aarhus, Denmark, and the German Cancer Research Centre. He has held a number of advisory posts, e.g. at WHO and the OECD. He served as a member of the German National Blood Advisory Board of the Ministry of Health and is currently a member of several Research Funding Committees e.g. at the Wellcome Trust, London, and the Global Health Innovation Fund, Tokyo, respectively.
                      • Lou Welebob
                        Director, Vela Research Singapore
                        Biography
                          Lou Welebob has over 28 years of combined scientific and commercial experience in the biotechnology and molecular diagnostics industries. Prior to his current position at Vela, Mr. Welebob co-founded and served as the Senior Vice President of Research & Development and Technology at Vela Diagnostics in Singapore from 2011 to 2015. While at Roche Diagnostics Corporation, he served as the Vice President of Global Program Management and Business Development from 2008 to 2011 and as the Vice President of Marketing, Services and Sales from 2005 to 2008. Mr. Welebob also held both scientific and commercial positions in several biotechnology companies and scientific research positions in several pharmaceutical companies. He received a B.S. in Chemistry from Wilkes University and was a Member of the National Research Honor Society (Sigma XI). He completed graduate coursework in biochemistry while at the University of Scranton and graduate coursework in chemistry at Rutgers University.
                        • Brian McNally, PhD
                          Senior Marketing Specialist, Canon BioMedical
                          Biography
                            Brian McNally received his doctorate in Cell & Molecular Biology at University of Texas Southwestern Medical Center, where he focused on the transcriptional mechanisms governing polycystic kidney disease, renal cancer and development. His post-doctoral fellowship concentrated on the regulatory relationship between the proteasome and Toll-like receptor signaling at the University of Maryland Medical School in the Department of Immunology and Microbiology. Brian has fifteen years of practical experience at the laboratory bench, and his work has been published in peer-reviewed journals and presented at international conferences. In 2008, he transitioned to industry to commercialize new biomedical products including assays, reagents and software. Brian has been with Canon BioMedical since its inception last year. He is passionate about partnering with life scientists to develop the next wave of biomedical solutions.
                          • William Clarke, PhD, MBA, DABCC
                            Director, Clinical Toxicology, Director, Point-of-Care Testing, Associate Professor of Pathology, Johns Hopkins Medical Institutions
                            Biography
                              Dr. Clarke received his Ph.D. in Analytical Chemistry from the University of Nebraska in Lincoln in 2000, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine, ending in 2002. In addition, he received an MBA focused on medical services management from the Carey School of Business at Johns Hopkins in 2007. Following his post-doctoral fellowship, he has remained at Johns Hopkins, where he is an Associate Professor in the Department of Pathology, as well as the director of both Point-of-Care Testing and TDM/Toxicology for the hospital. Dr. Clarke is board certified in Clinical Chemistry by the American Board of Clinical Chemistry, and is a Fellow of the National Academy of Clinical Biochemistry. His research interests include method development and evaluation for therapeutic drug monitoring, clinical toxicology, point-of-care testing, and development/validation of biomarkers for use in drug management. <br /> <br />&nbsp;Dr. Clarke has published 45 papers in journals such as Analytical Chemistry, Journal of Chromatography, Clin Chim Acta, and Annals of Surgery, as well as 22 book chapters. He is also the editor of Contemporary Practice in Clinical Chemistry, published by AACC Press. Dr. Clarke was the recipient of the 2004 George Grannis Award from the NACB for excellence in research and publication by a young investigator, and also the 2005 AACC TDM/Toxicology Division Young Investigator Award.
                            • Jennifer Colby, PhD, DABCC, FACB
                              Medical Director of Toxicology and Esoteric Chemistry; Vanderbilt University Medical Center
                              Biography
                                Jennifer M. Colby is an assistant professor in the department of Pathology, Microbiology, and Immunology and the medical director of Toxicology and Esoteric Chemistry at Vanderbilt University Medical Center. Jennifer earned her BS in Molecular and Cellular Biology from Vanderbilt University in 2007 and her PhD in Molecular Toxicology from the University of California Berkeley in 2012. She completed her postdoctoral training in clinical chemistry and toxicology at the University of California San Francisco in 2015. She is a member of SOFT, MATT, AACC, ACLPS, AACT, and IATDMCT. Her research interests include developing new applications for mass spectrometry in toxicology and laboratory medicine. When not in the lab Jennifer runs, competes in dressage, and enjoys exploring Tennessee with her Bouvier des Flandres.
                              • Steven Cotten, PhD DABCC
                                Assistant Professor Pathology, Director of Chemistry, Immunology, Toxicology, and Point of Care; Ohio State University Wexner Medical Center
                                Biography
                                  Dr. Cotten is Director for Chemistry, Immunology, Toxicology and Point-of-Care testing at the Ohio State University Wexner Medical Center and Assistant Professor in Pathology at the Ohio State University. He received his PhD in Pharmaceutical Sciences from the School of Pharmacy at the University of North Carolina at Chapel Hill where he also completed his training in clinical chemistry in the Department of Pathology. Dr. Cotten is board certified in Clinical Chemistry by the American Board of Clinical Chemistry. He has served as the chair of the AACC Ohio Valley Local Section and is currently the newsletter editor and online community moderator for the new Mass Spectrometry and Separation Sciences (MS3) Division of The American Association for Clinical Chemistry. His primary research interests include drug testing in alternative matrices and operational efficiency metrics for clinical laboratories.
                                • Sebastiano Gattoni-Celli, MD
                                  Professor of Radiation Oncology - Medical University of South Carolina, Health Research Scientist & Research Integrity Officer, Ralph H. Johnson VA Medical Center
                                  Biography
                                    Dr. Sebastiano Gattoni-Celli received his MD from the University of Naples Medical School before completing his Residency in Oncology at Catholic University Medical School in Rome and a Fellowship in Molecular Biology at New York University Medical Center. He is currently a Professor of Radiation Oncology at the Medical University of South Carolina and a Health Research Scientist at the Ralph H Johnson VA Medical Center in Charleston, SC. For the past decade, vitamin D3 supplementation studies have been an important aspect of his research efforts. Specifically, he has explored the impact that hypovitaminosis D can have on the health of very large segments of the population. Dr. Gattoni-Celli is currently examining the possibility that long-term vitamin D deficiency may contribute to the progression from subclinical prostate cancer to clinical disease, especially among African American men. Dr. Gattoni-Celli is actively conducting clinical trials to determine whether vitamin D3 supplementation in patients diagnosed with early-stage, low-risk prostate cancer will yield improved therapeutic clinical and survival outcomes.
                                  • Damien Gruson, PhD
                                    Professor, Associated Laboratory Director, Saint-Luc University Hospital, Brussels, Belgium
                                    Biography
                                      Professor Damien Gruson was awarded his degree of Pharmacist and later of Specialist in Laboratory Medicine from the Catholic University of Louvain, Brussels, Belgium. He joined the Department of Laboratory Medicine of the St-Luc University Hospital in 2008. He is now associated laboratory director and leading Endocrine Biology. He is also member of the research unit on Endocrinolgy Diabetes and Nutrition of the Catholic University of Louvain. Pr. D. Gruson has published numerous articles in several international peer-reviewed journals. Pr. D. Gruson is a member of the committee on distance learning of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), of the IFCC task force for young scientists (Chair between 2010 and 2012 and now consultant), a member of the division of Endocrinology of the American Association of Clinical Chemistry. Pr. D. Gruson is also a Fellow of the European Society of Cardiology.
                                    • Ellis Jacobs, PhD, DABCC, FACB
                                      Director, Scientific Affairs, Alere, Inc., Adjunct Assoc Professor of Pathology, Mount Sinai School of Medicine
                                      Biography
                                        Dr. Jacobs received his B.S. degree in Chemistry and Natural Sciences from Muhlenberg College in Allentown, PA and then obtained a Ph.D. in Biochemistry from the University of South Carolina. He did postdoctoral training in Clinical Chemistry & Toxicology at the University of North Carolina, Chapel Hill. Dr. Jacobs was a laboratory director at The Mount Sinai Hospital, Bellevue Medical Center and Henry J Carter and Coler-Goldwater Specialty Hospitals for over 25 years and has extensive experience with POCT, critical care testing, laboratory consolidation and automation, computerization and automatic result reporting, and planning and performance of clinical trials for various main laboratory and POCT systems. He has over 60 peer reviewed publications and textbook chapters and was the principal investigator on several beta site studies for various POCT analytical systems. Dr. Jacobs has been involved in establishing clinical diagnostic regulatory and accreditation standards at the local, national and international levels. He is a former director of the New York State laboratory accreditation program and is active in the Clinical and Laboratory Standards Institute. He is Chair of the CLSI Expert Panel on Point of Care Testing and was a member of the development committees for EP18 and EP23. Additionally, Dr. Jacobs is a past member, and current observer, of the US Technical Advisory Group for ISO Technical Committee 212 on Clinical Laboratory Testing and In Vitro Diagnostic Test Systems. Dr. Jacobs was the AACC Liaison to the Connectivity Industrial Consortium for POC Testing and was secretary & chair of both ANSA and the Point-of-Care Testing Division. He was a member of the NACB LMPG on Point of Care Testing Committee and is active in the International Federation of Clinical Chemistry. He is past chair of the Communications & Publications Division, was on several IFCC committees and working groups.
                                      • John McDevitt, PhD
                                        Chair, Department Biomaterials, New York University College of Dentistry and Bioengineering Institute & Chief Scientific Officer, Founder of SensoDx
                                        Biography
                                          Dr. John T. McDevitt is a pioneer in the development of the Programmable Bio-Nano-Chip (p-BNC) sensor systems. This universal mHealth platform technology has a capacity to digitize biological signatures for a broad range of key health conditions. These powerful mini-detection ensembles with multiplexed and multi-class (cellular, genomic, proteomic) capabilities have been developed and validated in the context of cancer diagnostics, cardiovascular disease, saliva-based diagnostics, infectious diseases, drugs of abuse detection and cell imaging systems. Further, over the past 5 years the McDevitt laboratory has secured an in-depth experience with management and execution of international, multi-site clinical studies that have resulted in the collection of unique databases using these p-BNC tools. These chip-based sensors have laid the foundation for the efficient collection of first-in-kind wellness and disease signatures for the areas of adjunctive oral cancer tests as well as for cardiac wellness profiles. McDevitt has displayed a strong track record of translating essential bioscience discoveries into real-world clinical practice. He serves as the Scientific Founder and Chief Scientific Officer for SensoDx, LLC. a diagnostic company committed to development of affordable medical microdevice technologies. Dr. McDevitt currently serves as the Chair for the Biomaterials Department at New York University's College of Dentistry. McDevitt and his team over the past decade have raised over $25M in Federal and Foundation support. McDevitt and his team have written more than 200 peer-reviewed scientific manuscripts and have contributed to more than 100 patents and patent applications. In addition to the "2016 AACC Wallace H. Coulter Lectureship Award", this work was recognized with the "Best of What's New Award" in the Medical Device Category for 2008 by Popular Science as well as for the "Best Scientific Advances Award" in 1998 by the Science Coalition.
                                        • Nihmat Morjana, Ph.D., M.Sc.
                                          Director; Siemens Healthineers
                                          Biography
                                            Nihmat Morjana, Ph.D., M.Sc. is a Director at Siemens Healthineers. Dr. Morjana received his Ph.D. in Biochemistry, from Queen's University working on the structure/mechanism and drug interaction of Aldo-Keto Reductases. Following his post-doctoral training at Baylor College of Medicine, he joined Baxter/Dade International/Dade Behring/Siemens. He led projects on the development and commercialization of drugs of abuse, pain management and immunosuppressant immunoassays. Dr. Morjana has 24 years of experience in the diagnostic industry. His current work focus includes immunoassay and application development on multiple-instruments. He is a member of ASBMB, SOFT and AACC and has published peer reviewed papers and abstracts and an inventor on patents. He is on the Editorial Board of Biotechnology and applied Biochemistry and served on the Editorial board of the Internet Journal of Genomics and Proteomics.
                                          • Keith Pardee, PhD
                                            Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
                                            Biography
                                              Dr. Pardee is an Assistant professor in the Leslie Dan Faculty of Pharmacy, at the University of Toronto. He holds an Honours Bachelor of Science degree in Biological Sciences from the University of Alberta, a Master of Science degree in Natural Products Chemistry from the University of British Columbia, and a Doctor of Philosophy degree in Molecular Genetics from the University of Toronto. Following the completion of his doctoral studies, Dr. Pardee completed a Postdoctoral Fellowship under the supervision of Professor James J. Collins at the Wyss Institute at Harvard University. Dr. Pardee's work at Harvard combined in vitro synthetic biology and biochemical systems with materials science to build paper-based synthetic gene networks. With this system he created a method to embed freeze-dried synthetic gene networks and their complementary cellular machinery into paper. These systems remain stable without refrigeration for more than a year, and are activated by adding water. These devices provide a new venue for synthetic biologists to operate in, and a much-needed path for the safe deployment of engineered gene circuits beyond the lab. With this technology he has developed diagnostics for the Zika virus (http://www.cell.com/fulltext/S0092-8674(16)30505-0) and as well as developed a new portable manufacturing platform for therapeutics (http://www.cell.com/fulltext/S0092-8674(16)31246-6). Dr. Pardee's research has been published in Cell, Nature, PLoS Biology, and Genes and Development, among others.
                                            • Ravinder Singh, PhD
                                              Director, Endocrine Laboratory, Mayo Clinic
                                              Biography
                                                Ravinder J. Singh, Ph.D., is the director of the Mayo Clinic Endocrine Laboratory. He has a focused area of investigation that has broad applicability to the field. Dr. Singh studies the application of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to clinical laboratory analysis. Many of the methods that Dr. Singh developed are now considered reference methods. They have subsequently been utilized for method standardization efforts as well as to establish clinical disease correlates, which he has published with his collaborators. Dr. Singh's work has directly contributed to improving methods for the clinical diagnosis of Cushing's disease, pheochromocytoma and congenital adrenal hyperplasia. He continues to work to discover innovative ways to better understand the uses of LC-MS/MS in providing patients with faster and more accurate diagnoses.
                                              • James Snider, PhD
                                                President, Critical Diagnostics
                                                Biography
                                                  Dr. James V. Snider, Ph.D., has been the President of Critical Care Diagnostics Inc. since August 2005 and serves as its Member of the Management Board. Prior to joining CCD in August 2005, Dr. Snider Served as a Executive Vice President of Business and Operations of Intelligent Medical Devices Inc. Dr. Snider joined Intelligent MD in October 2001 as Vice President of Marketing and Business Development. Prior to IMD, Dr. Snider served a series of marketing and product development positions at Applied Biosystems (ABI). In his last role at ABI, he managed the Sample Preparation Systems product line and team from genesis through product launch and successfully established it in the market. Before his eight-year tenure at AB, Dr. Snider served as Senior Scientist at Biotech Research Laboratories, a contracts and service research company specializing in retroviral technologies. He performed his post-doctoral research as a fellow in the Biological Response Modifiers Program at the Frederick Cancer Research & Development Center of the National Cancer Institute. Dr. Snider holds a BS in chemistry from Grand Valley State University, a PhD in chemistry from the University of South Carolina and an MBA in technology management from the University of Phoenix.
                                                Sponsors

                                                For information on becoming a sponsor or exhibitor, please click here.


                                                Continuing Education Credits

                                                The presentations below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the process to receive credits, and the accreditation bodies, please click here


                                                Committee

                                                To download the Program Committee brochure here.


                                                • Sihe Wang, PhD DABCC FACB

                                                  Dr. Sihe Wang is Section Head and Medical Director of Clinical Biochemistry and Director of Clinical Biochemistry Fellowship Training Program, Cleveland Clinic, Cleveland, Ohio. He also chairs the clinical chemistry integration effort for the Cleveland Clinic Health System which ...

                                                  Show more Show less
                                                • Christoph H. Borchers, Ph.D.

                                                  Dr. Borchers received his B.S., M.S. and Ph.D. from the University of Konstanz, Germany. After his post-doctoral training and employment as a staff scientist at NIEHS/NIH/RTP, NC and he was the director of the Duke - UNC Proteomics Facility and held a faculty position at UNC ...

                                                  Show more Show less
                                                • George Fritsma, MS, MT

                                                  George Fritsma is an associate professor in Laboratory Medicine of the Department of Pathology at the University of Alabama at Birmingham. Prof. Fritsma manages www.fritsmafactor.com, "The Fritsma Factor, Your Interactive Hemostasis Resource," a clinical coagulation ...

                                                  Show more Show less
                                                • Wieslaw Furmaga, MD

                                                  Director, Clinical Chemistry Laboratory University Hospital Director, General Laboratory Cancer Treatment Research Center Director, Proteomics Laboratory UTHSC at San Antonio Interim Director, Molecular Laboratory UTHSC at San Antonio Associate Director, Mycology Laboratory UTHSC ...

                                                  Show more Show less
                                                • Michael Holick, MD, PhD

                                                  Michael F. Holick, Ph.D., M.D. is Professor of Medicine, Physiology and Biophysics; Director of the General Clinical Research Unit; and Director of the Bone Health Care Clinic and the Director of the Vitamin D, Skin and Bone Research Laboratory at Boston University Medical ...

                                                  Show more Show less
                                                • Kamisha Johnson-Davis, PhD, DABCC, FACB

                                                  Dr. Johnson-Davis is a medical director of the Clinical Toxicology laboratory, Antifungal Testing and Immunosuppressants Testing at ARUP. Dr. Johnson-Davis received her PhD in pharmacology at the University of Utah and is board certified in clinical chemistry by the American ...

                                                  Show more Show less
                                                • Alan Maisel, MD

                                                  Dr. Alan Maisel attended University of Michigan Medical School and did his cardiology training at the University of California at San Diego. He is currently Professor of Medicine at the University and director of the coronary care unit and the heart failure program at the ...

                                                  Show more Show less
                                                • Mark Marzinke, PhD, BABCC

                                                  Mark Marzinke, PhD, DABCC earned a Ph.D. in Biochemistry from the University of Wisconsin-Madison and subsequently completed a clinical chemistry fellowship at The Johns Hopkins University in 2012. During his clinical fellowship, Dr. Marzinke focused on the development and ...

                                                  Show more Show less
                                                • Ross J Molinaro, PhD, MT(ASCP), DABCC, FACB

                                                  Ross J. Molinaro, PhD, MT(ASCP), DABCC, FACB is an Assistant Professor in the Department of Pathology and Laboratory Medicine at Emory University. He received his PhD in Clinical Chemistry and Molecular Medicine from Cleveland State University and completed the ComACC training ...

                                                  Show more Show less
                                                • Howard Morris, PhD, FAACB, FFSc(RCPA)

                                                  Professor Howard Morris is Professor of Medical Sciences at the University of South Australia and a Chief Medical Scientist in Chemical Pathology at SA Pathology, Adelaide, South Australia. He is currently Vice-President of the International Federation of Clinical Chemistry ...

                                                  Show more Show less
                                                • Joely Straseski, PhD, MS, MT(ASCP), DABCC

                                                  Dr. Straseski is a medical director of endocrinology at ARUP Laboratories and an assistant professor of pathology at the University of Utah School of Medicine. She received her PhD in pathology and laboratory medicine and a Master's degree in bacteriology from the University of ...

                                                  Show more Show less
                                                • Alan Wright, MD

                                                  Dr. Wright is the Chief Medical Officer at Roche Diagnostics Corporation in Indianapolis, Indiana. Prior to joining Roche, Dr. Wright served as Senior Vice President of Health Improvement Strategies for Miraca Life Sciences. He was the Vice President for Product Strategy and ...

                                                  Show more Show less
                                                Help

                                                General LabRoots Questions

                                                For bugs, spam, technical support or questions please call +1-714-463-4673 or email [email protected]  
                                                Contact us

                                                Virtual Events and Webinars

                                                Supported Configurations

                                                • Operating System Internet Explorer Firefox Chrome Safari
                                                  Vista IE8+ FF10+ Chrome15+
                                                  Windows 7 IE8+ FF10+ Chrome15+
                                                  Windows 8 IE10 FF10+ Chrome15+
                                                  Mac OS X   FF10+ Chrome15+ Safari5.1+
                                                • Cookie settings: session cookies enabled
                                                • Browser configuration must have JavaScript enabled
                                                • Adobe Flash player 10.2 or later

                                                To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                                Internet Connection

                                                • A minimum of 100Kbps is recommended for audio-only events
                                                • A minimum of 300Kbps is recommended for speaker on-video events

                                                Computer Equipment

                                                • Screen Resolution: Minimum 1024x768
                                                • Video Card: 65,000 colors minimum
                                                • Sound card and speakers (or headphones) for hearing webcast in full format
                                                • Audio Card: 16-bit minimum
                                                • RAM: 512MB of free RAM

                                                Firewall Protocol

                                                • HTTP on port 80 or HTTPS on port 443
                                                • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                                • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                                Work-At-Home Attendees

                                                • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                                For A Seamless Experience

                                                When using a mobile device, FREE Mobile Apps are available:

                                                - For viewing Webinars:

                                                - For viewing Virtual Events

                                                Attendee Guide

                                                • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                                Virtual Event and Webinar Support:

                                                Continuing Education (CME/CE) Support

                                                Loading Comments...
                                                Show Resources